ArticleWorld journal of oncology2026
Identification of Genes and Construction of Prognostic Model of Lung Adenocarcinoma Based on Propionate Metabolism-Related Genes.
Article in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysregulation of propionate metabolism can enhance the invasive properties of lung adenocarcinoma (LUAD) cells and increase their metastatic potential. Therefore, we constructed a predictive model based on propionate metabolism-related genes (PMRGs) to evaluate the prognosis of patients with LUAD. Methods: mRNA expression profiles and clinical data of LUAD patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). The predictive model was constructed using least absolute shrinkage and selection operator (LASSO). The associations between the risk score and tumor prognosis, immune infiltration, drug sensitivity, signaling pathways, and clinical features were evaluated using the CIBERSORT algorithm, the Genomics of Drug Sensitivity in Cancer (GDSC) database, gene set variation analysis (GSVA), gene set enrichment analysis (GSEA), and nomogram analyses. For hub genes, motif enrichment, genome-wide association study (GWAS) analysis and single-cell analysis were performed. Expression differences between LUAD cells and normal lung epithelial cells were validated using quantitative real-time polymerase chain reaction (qRT-PCR). Results: We established a LUAD prognostic model containing 16 hub genes. The area under the receiver operating characteristic curve (AUC) values for the model were 0.722 (1-year overall survival (OS)), 0.696 (3-year OS), and 0.700 (5-year OS). GSVA revealed significant enrichment in the G2/M checkpoint, E2F targets, and glycolysis pathways. GSEA indicated enrichment of the hypoxia-inducible factor-1 (HIF-1), interleukin (IL)-17, and p53 signaling pathways. Transcription factor analysis identified the motif cisbp-M4287 as the most significantly enriched, with a normalized enrichment score (NES) of 5.9. qRT-PCR results showed that the expression of ADIPOQ, CYP27A1, and GCDH was downregulated, while the expression of SERPINE1 was upregulated. No statistically significant differences were observed in the expression of CYP17A1 and EHHADH. Conclusions: A novel prognostic model based on PMRGs was established to predict overall survival in LUAD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.